Valchlor

Ceptaris wins FDA OK for lymphoma gel, clears path to $250M Actelion buyout
Fierce Biotech
Mon, 08/26/13 - 09:33 am
Actelion
FDA
Ceptaris
Valchlor
cutaneous T-cell lymphoma